The latest updates on our research and how it is improving people’s lives.
15 January 2021
The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.
18 December 2020
In a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of “living reviews” in Oxford University Press’s new open access journal “Oxford Open Immunology”.
Oxford University awarded £2.4 million to fund DPhil research in inflammation, immunology and musculoskeletal disease
18 December 2020
Oxford University has today been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.
11 December 2020
New research from the Kusumbe Group at the Kennedy Institute has shown a direct correlation between age-related decline in capillary and artery numbers and hormone production in the endocrine system.
£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships
10 December 2020
Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.
25 November 2020
People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.
13 November 2020
Professor Simon has been successful in her Wellcome Trust Investigator Award entitled: “Proteostasis and Autophagy in Immune Senescence.”
30 October 2020
In a collaboration with scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), Kennedy researchers have contributed to the discovery that neutrophils have many more functions in the body than previously thought. This finding suggests that neutrophil tissue-specific plasticity could be exploited in designing new treatments for neutrophil driven diseases, including cancer.
23 October 2020
Professor Marco Fritzsche has joined the Kennedy Institute as the Principal Investigator of the Biophysical Immunology Laboratory (BPI), as part of a joint appointment with the Rosalind Franklin Institute. His lab is leading the development of a lattice light sheet microscope that will significantly advance the study of live cells.
20 October 2020
A team from the University of Oxford has visualised how key cells of the immune system lock onto cancerous or infected cells to destroy them. The work was led by the Mike Dustin’s group at the Kennedy Institute of Rheumatology and experts in colorectal and ovarian cancers from across Oxford and computational biologists at the University of Birmingham.
19 October 2020
NDORMS researchers identify a subset of immune cells that could be a new therapeutic target to treat inflamed blood vessels in Giant Cell Arteritis (GCA) and other forms of inflammatory vascular disease.
2 October 2020
Researchers at the Kennedy Institute review the growing body of literature on the role of the microbiome in colorectal cancer
18 August 2020
Research shows how IL-22 interacts with KRAS mutant tumours to promote excessive growth in colorectal cancer
1 July 2020
Professor Mark Coles was recently appointed to the governing body of the University’s newest graduate college.
29 June 2020
The key to swift treatments to cure the pain of rheumatoid arthritis has been found in the joints of people with the condition who are in long- term remission.
22 June 2020
Recognised for the part he played in the discovery of anti-TNF therapy, Dr Feldmann is now exploring whether the antibody can be effective for COVID-19.